{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T17:49:57Z","timestamp":1793555397559,"version":"4.5.0"},"reference-count":184,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.autrev.2019.102429","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T19:50:55Z","timestamp":1573761055000},"page":"102429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":312,"title":["Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies"],"prefix":"10.1016","volume":"19","author":[{"given":"Jos\u00e9 Mar\u00eda G.","family":"Ruiz de Morales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Daud\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Pablos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Olveira","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Gonz\u00e1lez","family":"Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Ad\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalb\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Borruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Ort\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Holgado-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garc\u00eda-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Vizcaya-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Mart\u00edn-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.autrev.2019.102429_bb0005","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.4049\/jimmunol.1102576","article-title":"Life before seventeen: cloning of the IL-17 receptor","volume":"187","author":"Gaffen","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0010","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.molmed.2016.01.001","article-title":"IL-17 in chronic inflammation: from discovery to targeting","volume":"22","author":"Beringer","year":"2016","journal-title":"Trends Mol Med"},{"issue":"5","key":"10.1016\/j.autrev.2019.102429_bb0015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","article-title":"IL-17 signaling: the Yin and the Yang","volume":"38","author":"Amatya","year":"2017","journal-title":"Trends Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0020","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology"},{"issue":"12","key":"10.1016\/j.autrev.2019.102429_bb0030","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1038\/cti.2016.71","article-title":"Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity","volume":"5","author":"Okada","year":"2016","journal-title":"Clin Transl Immunol"},{"issue":"7248","key":"10.1016\/j.autrev.2019.102429_bb0035","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nature08068","article-title":"Dual nature of the adaptive immune system in lampreys","volume":"459","author":"Guo","year":"2009","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0040","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1189\/jlb.3HI1215-542R","article-title":"Human mast cells capture, store, and release bioactive, exogenous IL-17A","volume":"100","author":"Noordenbos","year":"2016","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2011-01-331298","article-title":"Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells","volume":"118","author":"Caccamo","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0050","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0055","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.autrev.2019.102429_bb0060","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/jdv.12272","article-title":"Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial","volume":"28","author":"Bissonnette","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0065","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.immuni.2013.09.002","article-title":"An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis","volume":"39","author":"Boisson","year":"2013","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.autrev.2019.102429_bb0070","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.10.046","article-title":"Targeting CD8(+) T cells prevents psoriasis development","volume":"138","author":"Di Meglio","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0080","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1172\/JCI78085","article-title":"Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity","volume":"125","author":"Burkett","year":"2015","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1189\/jlb.0211099","article-title":"Mechanisms controlling Th17 cytokine expression and host defense","volume":"90","author":"McAleer","year":"2011","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.autrev.2019.102429_bb0090","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1084\/jem.20071737","article-title":"If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine","volume":"204","author":"Ehrenstein","year":"2007","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.autrev.2019.102429_bb0100","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.crohns.2014.02.009","article-title":"Effect of interleukin-17 on gene expression profile of fibroblasts from Crohn's disease patients","volume":"8","author":"Kerami","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.autrev.2019.102429_bb0105","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/annrheumdis-2014-207110","article-title":"A cell-based bioassay for circulating bioactive IL-17: application to destruction in rheumatoid arthritis","volume":"74","author":"Ndongo-Thiam","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.autrev.2019.102429_bb0115","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Behcet patients with active uveitis","volume":"49","author":"Chi","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0120","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.immuni.2015.12.003","article-title":"Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions","volume":"43","author":"Patel","year":"2015","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.autrev.2019.102429_bb0125","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2019.102429_bb0130","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/BOR.0000000000000069","article-title":"The interleukin-23\/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis","volume":"26","author":"Yeremenko","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrd4518","article-title":"Targeting the IL-17-T(H)17 pathway","volume":"14","author":"Bartlett","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.autrev.2019.102429_bb0145","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/ard.2010.147033","article-title":"Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2019.102429_bb0150","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0155","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","article-title":"The translational revolution and use of biologics in patients with inflammatory skin diseases","volume":"135","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2019.102429_bb0160","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/exd.12487","article-title":"Cellular sources of IL-17 in psoriasis: a paradigm shift?","volume":"23","author":"Keijsers","year":"2014","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0165","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjd.15029","article-title":"Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy","volume":"177","author":"Jack","year":"2017","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2019.102429_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.13807","article-title":"Neutrophils are not the dominant interleukin-17 producer in psoriasis","volume":"44","author":"Yamanaka","year":"2017","journal-title":"J Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2019.102429_bb0175","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1172\/JCI93396","article-title":"Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing \u03b1\u03b2 T cell clones","volume":"127","author":"Matos","year":"2017","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2019.102429_bb0185","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0190","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2019.102429_bb0195","series-title":"Secukinumab provides long lasting complete relief for patients with difficult-to-treat palmoplantar, nail, and scalp psoriasis: results from 3 phase III placebo-controlled randomized trials","author":"Reich","year":"2018"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0200","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.16736","article-title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","volume":"179","author":"Ryan","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2019.102429_bb0205","first-page":"S7","article-title":"Long-term psoriasis control following secukinumab discontinuation indicates disease modification of moderate to severe psoriasis. Presented as a poster presentation at the 13th Annual Maui Derm for Dermatologists (2017)","volume":"10","author":"Lebwohl","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2019.102429_bb0210","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/jdv.14979","article-title":"Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification \u2013 rationale and design of the randomized, multicenter STEPIn study","volume":"32","author":"Iversen","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2019.102429_bb0215","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/annrheumdis-2018-eular.3904","article-title":"OP0305 Disease interception in psoriasis patients with subclinical joint inflammation by interleukin 17 inhibition with secukinumab \u2013 data from a prospective open label study","volume":"77","author":"Kampylafka","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0220","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/ced.12567","article-title":"The role of interleukin-17 in mouse models of atopic dermatitis and contact dermatitis","volume":"40","author":"Heo","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2019.102429_bb0225","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/jid.2014.51","article-title":"IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models","volume":"134","author":"Nakajima","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0230","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/jdv.12753","article-title":"Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1\/Th2\/Th17 cytokines in adults with atopic dermatitis","volume":"29","author":"Batista","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0235","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1203475417697651","article-title":"Establishing a role for interleukin-17 in atopic dermatitis-related skin inflammation","volume":"21","author":"Tan","year":"2017","journal-title":"J Cutan Med Surg"},{"issue":"4S","key":"10.1016\/j.autrev.2019.102429_bb0240","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000350933","article-title":"Alopecia areata: infiltration of Th17 cells in the dermis, particularly around hair follicles","volume":"226","author":"Tanemura","year":"2013","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0250","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/0300060514549784","article-title":"Investigation of interleukin-12, interleukin-17 and interleukin-23 receptor gene polymorphisms in alopecia areata","volume":"43","author":"Aytekin","year":"2015","journal-title":"J Int Med Res"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0255","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00403-016-1617-z","article-title":"B cell activating factor and T-helper 17 cells: possible synergistic culprits in the pathogenesis of alopecia areata","volume":"308","author":"Elela","year":"2016","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0260","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0265","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 10","key":"10.1016\/j.autrev.2019.102429_bb0270","article-title":"Anti-IL-17A treatment blocks inflammation, destruction and new bone formation in experimental spondyloarthritis in HLA-B27 transgenic rats","volume":"67","author":"Van Tok","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2019.102429_bb0275","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2015.10.013","article-title":"Mediators of inflammation and bone remodeling in rheumatic disease","volume":"49","author":"Shaw","year":"2016","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0280","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/annrheumdis-2013-204782","article-title":"IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis","volume":"74","author":"Adamopoulos","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0285","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/art.40770","article-title":"Interleukin-17A inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis","volume":"71","author":"van Tok","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"57","key":"10.1016\/j.autrev.2019.102429_bb0290","doi-asserted-by":"crossref","first-page":"96993","DOI":"10.18632\/oncotarget.20823","article-title":"Interleukin-17A-promoted MSC2 polarization related with new bone formation of ankylosing spondylitis","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0295","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/imm.12142","article-title":"Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis","volume":"141","author":"Kirkham","year":"2014","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0300","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0305","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/ar3817","article-title":"Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features","volume":"14","author":"Celis","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0310","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis","volume":"64","author":"Noordenbos","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0315","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/key331","article-title":"Histologic evidence that mast cells contribute to local tissue inflammation in peripheral spondyloarthritis by regulating interleukin-17A content","volume":"58","author":"Chen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2019.102429_bb0320","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0325","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","article-title":"Cutting edge: homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis","volume":"200","author":"Soare","year":"2018","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0330","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.autrev.2016.09.015","article-title":"Are psoriasis and psoriatic arthritis the same disease? The IL-23\/IL-17 axis data","volume":"16","author":"Sakkas","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0335","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0340","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000723","article-title":"Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2019.102429_bb0345","series-title":"2018 ACR\/ARHP Annual Meeting: Arthritis Rheumatol","article-title":"Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5 year efficacy and safety results from a phase 3 trial","author":"Mease","year":"2018"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2019.102429_bb0350","first-page":"195","article-title":"Secukinumab improves axial manifestations in patients with psoriatic arthritis and inadequate response to NSAIDS: primary analysis of the maximise trial","volume":"78","author":"Baraliakos","year":"2019","journal-title":"Am Coll Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0355","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","article-title":"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study","volume":"20","author":"Kampylafka","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.autrev.2019.102429_bb0360","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2340\/00015555-2657","article-title":"Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis: a nationwide cohort study","volume":"97","author":"Egeberg","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"10.1016\/j.autrev.2019.102429_bb0365","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0370","article-title":"Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0375","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/BOR.0000000000000239","article-title":"Subclinical gut inflammation in ankylosing spondylitis","volume":"28","author":"Ciccia","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0380","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0385","first-page":"50","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0390","doi-asserted-by":"crossref","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-term\u00a0efficacy of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase 3 MEASURE 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open."},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0395","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40070","article-title":"Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled study","volume":"69","author":"Blanco","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2019.102429_bb0400","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13075-015-0688-0","article-title":"Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis","volume":"17","author":"Canete","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2019.102429_bb0405","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","article-title":"The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling","volume":"9","author":"van Tok","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2019.102429_bb0410","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2019.102429_bb0415","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.autrev.2018.06.008","article-title":"IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases","volume":"17","author":"Beringer","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2019.102429_bb0420","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.4049\/jimmunol.181.11.7473","article-title":"Requirement of IL-17RA in Con A induced hepatitis and negative regulation of IL-17 production in mouse T cells","volume":"181","author":"Nagata","year":"2008","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0425","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/icb.2011.59","article-title":"Critical role of interleukin-17\/interleukin-17 receptor axis in mediating Con A-induced hepatitis","volume":"90","author":"Yan","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.autrev.2019.102429_bb0430","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1746-1596-8-40","article-title":"Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection","volume":"8","author":"Du","year":"2013","journal-title":"Diagn Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0435","first-page":"13","article-title":"Th17 and IL-17 immunity in chronic hepatitis C infection","volume":"50","author":"B\u0103l\u0103nescu","year":"2012","journal-title":"Rom J Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0440","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22680","article-title":"The interleukin-17 pathway is involved in human alcoholic liver disease","volume":"49","author":"Lemmers","year":"2009","journal-title":"Hepatology"},{"issue":"44","key":"10.1016\/j.autrev.2019.102429_bb0445","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001888","article-title":"The distribution and the fibrotic role of elevated inflammatory Th17 cells in patients with primary biliary cirrhosis","volume":"94","author":"Shi","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0450","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/lt.21724","article-title":"Changes in the serum levels of interleukin-17\/interleukin-23 during acute rejection in liver transplantation","volume":"15","author":"F\u00e1brega","year":"2009","journal-title":"Liver Transpl"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0455","first-page":"9647","article-title":"Activation of the TLR4\/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL-23 and IL-17A","volume":"15","author":"Kang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.autrev.2019.102429_bb0460","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/436450","article-title":"Therapeutic potential of IL-17-mediated signaling pathway in autoimmune liver diseases","volume":"2015","author":"Zhang","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0470","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0475","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0480","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4254\/wjh.v7.i3.315","article-title":"Non-alcoholic fatty liver disease and psoriasis: so far so near","volume":"7","author":"Ganzetti","year":"2015","journal-title":"World J Hepatol"},{"issue":"8","key":"10.1016\/j.autrev.2019.102429_bb0485","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/apt.12038","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study","volume":"36","author":"Gerber","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0490","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Pt 1","key":"10.1016\/j.autrev.2019.102429_bb0495","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.mce.2015.02.018","article-title":"Metabolic syndrome and nonalcoholic fatty liver disease: is insulin resistance the link?","volume":"418","author":"Asrih","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"10.1016\/j.autrev.2019.102429_bb0500","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2174\/1389450116666150531153627","article-title":"IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression","volume":"16","author":"Giles","year":"2015","journal-title":"Curr Drug Targets"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0505","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/hep.23253","article-title":"Major histocompatibility complex class I-related chains A and B (MIC A\/B): a novel role in nonalcoholic steatohepatitis","volume":"51","author":"Kahraman","year":"2010","journal-title":"Hepatology"},{"issue":"33","key":"10.1016\/j.autrev.2019.102429_bb0510","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.3748\/wjg.v13.i33.4504","article-title":"Association of the frequency of peripheral natural killer T cells with nonalcoholic fatty liver disease","volume":"13","author":"Xu","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0515","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cytogfr.2010.10.005","article-title":"IL-17 in obesity and adipogenesis","volume":"21","author":"Ahmed","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0520","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2249.2011.04471.x","article-title":"Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease","volume":"166","author":"Tang","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2019.102429_bb0525","first-page":"221","article-title":"Molecular pathways in non-alcoholic fatty liver disease","volume":"7","author":"Berlanga","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"issue":"5","key":"10.1016\/j.autrev.2019.102429_bb0530","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1665-2681(19)31247-5","article-title":"Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease","volume":"13","author":"Wenfeng","year":"2014","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0535","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.05.049","article-title":"Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice","volume":"143","author":"Meng","year":"2012","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0540","first-page":"344","article-title":"Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology","volume":"3","author":"Weiskirchen","year":"2014","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0545","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0550","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2016.05.020","article-title":"Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma","volume":"30","author":"Gomes","year":"2016","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.autrev.2019.102429_bb0555","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0560","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cellimm.2011.08.015","article-title":"Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1\/Th17 cytokines and up-regulated T regulatory cells","volume":"271","author":"Li","year":"2011","journal-title":"Cell Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0565","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12026-008-8019-z","article-title":"Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response","volume":"41","author":"Zhang","year":"2008","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2019.102429_bb0570","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1741-7015-9-85","article-title":"Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes","volume":"9","author":"Barchetta","year":"2011","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.autrev.2019.102429_bb0575","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1046\/j.1365-2036.2001.01083.x","article-title":"Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study","volume":"15","author":"Hasegawa","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2019.102429_bb0580","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/253046","article-title":"Anti-IL-17 antibody improves hepatic steatosis by suppressing interleukin-17-related fatty acid synthesis and metabolism","volume":"2013","author":"Shi","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0585","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/CS20150405","article-title":"The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice","volume":"130","author":"Rolla","year":"2016","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0590","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.109.145094","article-title":"Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction","volume":"55","author":"Madhur","year":"2010","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.autrev.2019.102429_bb0595","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.autrev.2017.07.023","article-title":"Are cytokines and chemokines suitable biomarkers for Takayasu arteritis?","volume":"16","author":"Savioli","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2019.102429_bb0600","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/eurheartj\/ehs399","article-title":"Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown","volume":"34","author":"Liuzzo","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2019.102429_bb0605","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijcard.2015.06.152","article-title":"Interleukin-17 inhibition: an important target for attenuating myocardial ischemia and reperfusion injury","volume":"198","author":"Chen","year":"2015","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0610","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jacc.2011.10.863","article-title":"Interleukin-17A contributes to myocardial ischemia\/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration","volume":"59","author":"Liao","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.autrev.2019.102429_bb0615","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/eurheartj\/ehs263","article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction","volume":"34","author":"Simon","year":"2013","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0620","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"9","key":"10.1016\/j.autrev.2019.102429_bb0625","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.autrev.2017.07.009","article-title":"Effects of interleukin 17 on the cardiovascular system","volume":"16","author":"Robert","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0630","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clim.2011.07.003","article-title":"IL-17 induces apoptosis of vascular endothelial cells: a potential mechanism for human acute coronary syndrome","volume":"141","author":"Zhu","year":"2011","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2019.102429_bb0635","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.autrev.2019.102429_bb0640","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00109-014-1176-8","article-title":"IL-17A promotes ventricular remodeling after myocardial infarction","volume":"92","author":"Zhou","year":"2014","journal-title":"J Mol Med (Berl)"},{"issue":"11","key":"10.1016\/j.autrev.2019.102429_bb0645","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1016\/j.bbamcr.2016.08.013","article-title":"Interleukin-17A mediates cardiomyocyte apoptosis through Stat3-iNOS pathway","volume":"1863","author":"Su","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"27","key":"10.1016\/j.autrev.2019.102429_bb0650","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004105","article-title":"Common variants in IL-17A\/IL-17RA axis contribute to predisposition to and progression of congestive heart failure","volume":"95","author":"Sandip","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0655","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/exd.13467","article-title":"Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities","volume":"27","author":"Krueger","year":"2018","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0660","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/bjophthalmol-2014-306106","article-title":"Specific association of IL17A genetic variants with panuveitis","volume":"99","author":"Mucientes","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2019.102429_bb0665","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/396204","article-title":"Proinflammatory cytokines and C-reactive protein in uveitis associated with Behcet's disease","volume":"2014","author":"Mesquida","year":"2014","journal-title":"Mediat Inflamm"},{"issue":"52","key":"10.1016\/j.autrev.2019.102429_bb0670","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0675","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.autrev.2019.102429_bb0680","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0685","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173301","article-title":"Analysis of Th17-associated cytokines and clinical correlations in patients with dry eye disease","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0690","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5301\/ejo.5000712","article-title":"Interleukin-17 and its correlation with vascular endothelial growth factor expression in ocular surface pathologies: a histologic study","volume":"26","author":"Jabarin","year":"2016","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0695","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/0300060516672369","article-title":"Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy","volume":"44","author":"Chen","year":"2016","journal-title":"J Int Med Res"},{"issue":"10","key":"10.1016\/j.autrev.2019.102429_bb0700","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm1651","article-title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2019.102429_bb0705","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jneuroim.2018.08.001","article-title":"Th17 pathway signatures in a large Indian cohort of Guillain Barr\u00e9 syndrome","volume":"323","author":"Debnath","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/j.autrev.2019.102429_bb0710","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.21652","article-title":"T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta","volume":"65","author":"Durelli","year":"2009","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0715","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","article-title":"Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis","volume":"172","author":"Tzartos","year":"2008","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0720","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41467-017-01571-8","article-title":"Transcriptional signature of human pro-inflammatory T","volume":"8","author":"Hu","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0725","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/1352458516640609","article-title":"Th17 cells: a prognostic marker for MS rebound after natalizumab cessation?","volume":"23","author":"Haas","year":"2017","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.autrev.2019.102429_bb0730","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.4049\/jimmunol.1201476","article-title":"The role of IL-15 in activating STAT5 and fine-tuning IL-17A production in CD4 T lymphocytes","volume":"189","author":"Pandiyan","year":"2012","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2019.102429_bb0735","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdova","year":"2016","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0740","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s10875-013-9965-3","article-title":"Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barr\u00e9 syndrome","volume":"34","author":"Han","year":"2014","journal-title":"J Clin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2019.102429_bb0745","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00401-015-1402-7","article-title":"The role of IL-17 in CNS diseases","volume":"129","author":"Waisman","year":"2015","journal-title":"Acta Neuropathol"},{"issue":"7","key":"10.1016\/j.autrev.2019.102429_bb0750","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.biopsych.2012.09.021","article-title":"Inflammatory T helper 17 cells promote depression-like behavior in mice","volume":"73","author":"Beurel","year":"2013","journal-title":"Biol Psychiatry"},{"issue":"10127","key":"10.1016\/j.autrev.2019.102429_bb0755","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0760","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010024","article-title":"Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action","volume":"8","author":"Behrangi","year":"2019","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.autrev.2019.102429_bb0765","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/ibd.20475","article-title":"IL-23\/IL-17 immunity as a hallmark of Crohn's disease","volume":"14","author":"Holtta","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.1016\/j.autrev.2019.102429_bb0770","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00011-014-0768-7","article-title":"Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease","volume":"63","author":"Jiang","year":"2014","journal-title":"Inflamm Res"},{"issue":"7422","key":"10.1016\/j.autrev.2019.102429_bb0775","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2019.102429_bb0780","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn's disease","volume":"11","author":"MacDonald","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.autrev.2019.102429_bb0785","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","article-title":"Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study","volume":"3","author":"Feagan","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.autrev.2019.102429_bb0790","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.autrev.2019.102429_bb0795","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2012-304154","article-title":"Secukinumab failure in Crohn's disease: the yeast connection?","volume":"62","author":"Colombel","year":"2013","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.autrev.2019.102429_bb0800","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/gutjnl-2012-302525","article-title":"Seventeen in Crohn's disease: less prime than we thought?","volume":"61","author":"Raine","year":"2012","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.autrev.2019.102429_bb0805","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0810","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrc2804","article-title":"Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer","volume":"10","author":"Jenq","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"10.1016\/j.autrev.2019.102429_bb0815","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","article-title":"Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria","volume":"118","author":"Arai","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0820","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0825","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2008-06-162420","article-title":"In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations","volume":"113","author":"Carlson","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.autrev.2019.102429_bb0830","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1182\/blood-2015-01-622662","article-title":"Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects","volume":"126","author":"Gartlan","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0835","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2013-07-514372","article-title":"Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease","volume":"123","author":"Bruggen","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.autrev.2019.102429_bb0840","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2016-08-732628","article-title":"Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome","volume":"129","author":"Varelias","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.autrev.2019.102429_bb0845","article-title":"Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0850","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbrc.2011.03.021","article-title":"IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma","volume":"407","author":"Liu","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0855","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.lungcan.2009.11.013","article-title":"Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients","volume":"69","author":"Chen","year":"2010","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.autrev.2019.102429_bb0860","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/bcr2195","article-title":"IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines","volume":"10","author":"Zhu","year":"2008","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.autrev.2019.102429_bb0865","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1006\/bbrc.2001.4618","article-title":"Expression of IL-17 mRNA in ovarian cancer","volume":"282","author":"Kato","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.autrev.2019.102429_bb0870","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/onc.2013.537","article-title":"Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer","volume":"34","author":"Xiang","year":"2015","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0875","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ijc.20373","article-title":"Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome)","volume":"112","author":"Ciree","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.autrev.2019.102429_bb0880","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cyto.2015.09.011","article-title":"Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis","volume":"89","author":"Qian","year":"2017","journal-title":"Cytokine"},{"issue":"10","key":"10.1016\/j.autrev.2019.102429_bb0885","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1158\/0008-5472.CAN-08-0206","article-title":"Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17","volume":"68","author":"Nam","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.autrev.2019.102429_bb0890","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000055357","article-title":"Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice","volume":"61","author":"Hirahara","year":"2001","journal-title":"Oncology"},{"issue":"7","key":"10.1016\/j.autrev.2019.102429_bb0895","article-title":"Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression","volume":"6","author":"Li","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.autrev.2019.102429_bb0900","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.4049\/jimmunol.0902574","article-title":"IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells","volume":"184","author":"He","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102429_bb0905","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fimmu.2014.00276","article-title":"Th17 cells in cancer: the ultimate identity crisis","volume":"5","author":"Bailey","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2019.102429_bb0910","first-page":"39","article-title":"Interleukin-17 and type 17 helper T cells in cancer management and research","volume":"3","author":"Llosa","year":"2014","journal-title":"Immunotargets Ther"},{"issue":"4","key":"10.1016\/j.autrev.2019.102429_bb0915","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.4049\/jimmunol.0900568","article-title":"IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells","volume":"183","author":"Murugaiyan","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102429_bb1005","first-page":"1935","volume":"202","author":"Ramirez-Carrozzi","year":"2019"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:17:02Z","timestamp":1761599822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219302393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":184,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1568997219302393"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102429","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102429"}}